Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor-associated periodic syndrome

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 273-283

  Nedjai, Belinda ^a   Hitman, Graham A ^a   Yousaf, Nasim ^a   Chernajovsky, Yuti ^a   Stjernberg Salmela, Susanna ^b   Pettersson, Tom ^b   Ranki, Annamari ^b   Hawkins, Philip N ^c   Arkwright, Peter D ^d   McDermott, Michael F ^e   Turner, Mark D ^a,f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f Institute of Cell and Molecular Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PROTEIN SUBUNIT; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CELL SURFACE; CONTROLLED STUDY; GENE; GENE MUTATION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TNFRSF1A GENE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 38149024911     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23123     Document Type: Article

References (34)

1. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kd TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.
2. Sarrauste de Menthiere CS, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003;31:282-5.
3. Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C, et al. Infevers: an evolving mutation database for autoinflammatory syndromes. Hum Mutat 2004;24:194-8.
4. Kriegel MA, Huffmeier U, Scherb E, Scheidig C, Geiler T, Kalden JR, et al. Tumor necrosis factor receptor-associated periodic syndrome characterized by a mutation affecting the cleavage site of the receptor: implications for pathogenesis. Arthritis Rheum 2003;48:2386-8.
5. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 2002;81:349-68.
6. Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumour necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001;69:301-14.
7. May MJ, Ghosh S. Rel/NF-κB and IκB proteins: an overview. Semin Cancer Biol 1997;8:63-73.
8. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.
9. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
10. Moynagh PN. The NF-κB pathway. J Cell Sci 2005;118:4389-92.
11. Kunsch C, Ruben SM, Rosen CA. Selection of optimal κB/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol Cell Biol 1992;12:4412-21.
12. Todd I, Radford PM, Draper-Morgan KA, McIntosh R, Bainbridge S, Dickinson P, et al. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004;113:65-79.
13. Siebert S, Fielding CA, Williams BD, Brennan P. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-κB activation due to decreased cell surface expression. FEBS Lett 2005;579:5193-8.
14. Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006;108:1320-7.
15. Arkwright PD, McDermott MF, Houten SM, Frenkel J, Waterham HR, Aganna E, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002;130:484-8.
16. Yousaf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, Turner MD, et al. Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation. Arthritis Rheum 2005;52:2906-16.
17. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes. Proc Natl Acad Sci U S A 2000;97:1014-9.
18. Bradley JR, Thiru S, Pober JS. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol 1995;146:27-32.
19. Jones SJ, Ledgerwood EC, Prins JB, Galbraith J, Johnson DR, Pober JS, et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999;162:1042-8.
20. Gaeta ML, Johnson DR, Kluger MS, Pober JS. The death domain of tumor necrosis factor receptor 1 is necessary but not sufficient for Golgi retention of the receptor and mediates receptor desensitization. Lab Invest 2000;80:1185-94.
21. Storey H, Stewart A, Vandenabeele P, Luzio JP. The p55 tumour necrosis factor receptor TNFR1 contains a trans-Golgi network localization signal in the C-terminal region of the cytoplasmic tail. Biochem J 2002;366:15-22.
22. Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S, et al. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003;278:21751-60.
23. Siebert S, Amos N, Fielding CA, Wang EC, Aksentijevich I, Williams BD, et al. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum 2005;52:1287-92.
24. D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006;54:998-1008.
25. Todd I, Nowlan ML, Drewe E, Tighe PJ, Powell RJ. Heterogeneity of tumor necrosis factor receptor-associated periodic syndrome: comment on the article by Siebert et al [letter]. Arthritis Rheum 2005;52:2952.
26. Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N, et al. Regulation of an essential innate immune response by the p50 subunit of NF-κB. J Clin Invest 1998;102:1645-52.
27. Kastenbauer S, Ziegler-Heitbrock HW. NF-κB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect Immun 1999;67:1553-9.
28. Tong X, Yin L, Washington R, Rosenberg DW, Giardina C. The p50-p50 NF-κB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem 2004;265:171-83.
29. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, et al. The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 1993;72:729-39.
30. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev 1993;7,1354-63.
31. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene 1999;18,3316-23.
32. Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003;48:2632-44.
33. Stjernberg-Salmela S, Pettersson T, Karenko L, Blazevic V, Nevala H, Pitkanen S, et al. A novel tumour necrosis factor receptor mutation in a Finnish family with periodic fever syndrome. Scand J Rheumatol 2004;33:140-4.
34. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 1993;73:431-45.